Publication: Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence.
| dc.contributor.author | Lamanna-Rama, N | |
| dc.contributor.author | MacDowell, K S | |
| dc.contributor.author | López, G | |
| dc.contributor.author | Leza, J C | |
| dc.contributor.author | Desco, M | |
| dc.contributor.author | Ambrosio, E | |
| dc.contributor.author | Soto-Montenegro, M L | |
| dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
| dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
| dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
| dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERSAM (Salud Mental) | es_ES |
| dc.contributor.funder | Ministerio de Sanidad (España) | es_ES |
| dc.contributor.funder | Fundación Alicia Koplowitz | es_ES |
| dc.contributor.funder | Plan Nacional de Drogas (España) | es_ES |
| dc.contributor.funder | Instituto de Investigación Sanitaria Gregorio Marañón | es_ES |
| dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | es_ES |
| dc.date.accessioned | 2024-05-06T11:19:55Z | |
| dc.date.available | 2024-05-06T11:19:55Z | |
| dc.date.issued | 2023-04 | |
| dc.description.abstract | This study evaluates the long-term effects of a six and 14-week morphine withdrawal in rats pretreated with a cannabinoid agonist (CP-55,940, CP) during periadolescence. Wistar rats (33 males; 32 females) were treated with CP or its vehicle (VH) from postnatal day (PND) 28-38. At PND100, rats performed morphine self-administration (MSA, 15d/12 h/session). Eight groups were defined according to pretreatment (CP), treatment (morphine), and sex. Three [18F]FDG-PET brain images were acquired: after MSA, and after six and 14 weeks of withdrawal. PET data were analyzed with SPM12. Endocannabinoid (EC) markers were evaluated in frozen brain tissue at endpoint. Females showed a higher mean number of self-injections than males. A main Sex effect on global brain metabolism was found. FDG uptake in males was discrete, whereas females showed greater brain metabolism changes mainly in areas of the limbic system after morphine treatment. Moreover, the morphine-induced metabolic pattern in females was exacerbated when CP was previously present. In addition, the CP-Saline male group showed reduced CB1R, MAGL expression, and NAPE/FAAH ratio compared to the control group, and morphine was able to reverse CB1R and MAGL expression almost to control levels. In conclusion, females showed greater and longer-lasting metabolic changes after morphine withdrawal than males, indicating a higher vulnerability and a different sensitivity to morphine in subjects pre-exposed to CP. In contrast, males primarily showed changes in EC markers. Together, our results suggest that CP pre-exposure contributes to the modulation of brain metabolism and EC systems in a sex-dependent manner. | es_ES |
| dc.description.peerreviewed | Sí | es_ES |
| dc.description.sponsorship | MLS was supported by the Ministerio de Ciencia e Innovacion, Instituto de Salud Carlos III (project number PI17/01,766, and grant number BA21/00030), co-financed by the European Regional Development Fund (ERDF), "A way to make Europe"; project PID2021-128862OB-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE; CIBER de Salud Mental; Instituto de Salud Carlos III (project number CB07/09/0031), Ministerio de Sanidad (Delegacion del Gobierno para el Plan Nacional sobre Drogas, projects 2017/085, 2022/008917); and Fundacion Alicia Koplowitz. EA was supported by grants from Instituto de Salud Carlos III (Redes de Investigacion Cooperativa Orientadas a Resultados en Salud (RICORS): Red de Investigacion en Atencion Primaria de Adicciones (RIAPAd, RD21/0009/0020), Ministerio de Sanidad (Delegacion del Gobierno para el Plan Nacional sobre Drogas, 2021I043), Ministerio de Ciencia e Innovacion (PID2019-111594RB-100), UNED (Plan de Promocion de la Investigacion 2019-2021), and the European Union ' s Justice Programme-Drugs Policy Initiatives (JUST-2017-AGDRUGS-806996-JUSTSO). NLR was supported by Instituto de Investigacion Sanitaria Gregorio Maranon, "Programa Intramural de Impulso a la I+D+I 2019. MD was supported by Ministerio de Ciencia e Innovacion and Instituto de Salud Carlos III (ISCIII) (PT20/00044) and CIBER de Salud Mental, Instituto de Salud Carlos III (project number CB07/09/0031). JCL was supported by the Ministerio de Economia y Competitividad, MINECO-EU-FEDER (SAF2016-75500-R) and Ministerio de Ciencia e Innovacion (PID2019-109033RB-I00). The CNIC is supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovacion, and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV2015-0505). | es_ES |
| dc.format.page | 60 | es_ES |
| dc.format.volume | 69 | es_ES |
| dc.identifier.citation | Eur Neuropsychopharmacol. 2023 Apr:69:60-76. | es_ES |
| dc.identifier.doi | 10.1016/j.euroneuro.2023.01.005 | es_ES |
| dc.identifier.e-issn | 1873-7862 | es_ES |
| dc.identifier.journal | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | es_ES |
| dc.identifier.pubmedID | 36780817 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/19243 | |
| dc.language.iso | eng | es_ES |
| dc.publisher | Elsevier | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI17/01/766 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/BA21/00030 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PID2021-128862OB-100 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CB07/09/0031 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/2017/085 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/2022/008917 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD21/0009/0020 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PID2019-111594RB-100 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PT20/00044 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CB07/09/0031 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/ID2019-109033RB-I00 | es_ES |
| dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SEV2015-0505 | es_ES |
| dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/JUST-2017-AGDRUGS-806996-JUSTSO | es_ES |
| dc.relation.publisherversion | 10.1016/j.euroneuro.2023.01.005 | es_ES |
| dc.repisalud.institucion | CNIC | es_ES |
| dc.repisalud.orgCNIC | CNIC::Unidades técnicas::Imagen Avanzada | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject.mesh | Morphine | es_ES |
| dc.subject.mesh | Substance Withdrawal Syndrome | es_ES |
| dc.subject.mesh | Female | es_ES |
| dc.subject.mesh | Rats | es_ES |
| dc.subject.mesh | Animals | es_ES |
| dc.subject.mesh | Male | es_ES |
| dc.subject.mesh | Cannabinoid Receptor Agonists | es_ES |
| dc.subject.mesh | Rats, Wistar | es_ES |
| dc.subject.mesh | Fluorodeoxyglucose F18 | es_ES |
| dc.subject.mesh | Endocannabinoids | es_ES |
| dc.subject.mesh | Neuroimaging | es_ES |
| dc.subject.mesh | Glucose | es_ES |
| dc.title | Neuroimaging revealed long-lasting glucose metabolism changes to morphine withdrawal in rats pretreated with the cannabinoid agonist CP-55,940 during periadolescence. | es_ES |
| dc.type | journal article | es_ES |
| dc.type.hasVersion | VoR | es_ES |
| dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Neuroimaging revealed long-lasting_Eur Neuropsychopharmacol_2023.pdf
- Size:
- 309.66 KB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo


